Rosuvastatin ORBITAL Germany

Study identifier:D3560L00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effects of a twelve months ROSUVASTATIN treatment plus additional care (drug intake adherence and lifestyle enhancing initiatives ) compared to ROSUVASTATIN treatment alone on long-term disease-related costs in patients with an indication for statin treatment according to the Joint European Guidelines

Medical condition

Hypercholesterolemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin

Sex

All

Actual Enrollment

8000

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2002

Primary Completion Date: -

Study Completion Date: 01 Feb 2004

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Investigators

Principal Investigator

Wolfgang Meyer - Sabellek

AstraZeneca Germany